ArticleClinical and molecular allergy : CMA2017
Clinical management, expectations, and satisfaction of patients with moderate to severe allergic rhinoconjunctivitis treated with SQ-standardized grass-allergen tablet under routine clinical practice conditions in Spain.
Article in Clinical and molecular allergy : CMA, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical Practice Guideline: Immunotherapy for Inhalant Allergy.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2024Guideline
- Exploring novel systemic biomarker approaches in grass-pollen sublingual immunotherapy using omics.Allergy · 2021Trial
- Review
- Efficacy of subcutaneous allergen immunotherapy in atopic dogs: A retrospective study of 664 cases.Veterinary dermatology · 2022Article
- [Retrospective Study of Mite-Specific Subcutaneous Immunotherapy in Children].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2021Article
- ARIA 2019 Care Pathways for Allergic Rhinitis in the Kuwait Health Care System.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2021Review
- Understanding Patient Expectations of Health Care: A Qualitative Study.Journal of patient experience · 2020Article
- ARIA 2019, Allerjik Rinite Tedavi Yaklaşımı-Türkiye.Turkish thoracic journal · 2020Review
- ARIA guideline 2019: treatment of allergic rhinitis in the German health system.Allergologie select · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSublingual immunotherapy has been proven as a well-tolerated and effective treatment for allergic rhinitis. Within this type of treatment, GRAZAX
methodsThis was a non-interventional, observational, multi-centre, open-label study involving a total of 131 adult patients aged 18-66 years with confirmed diagnosis of grass-allergy and initiated treatment with GRAZAX
resultsIn the pollen season after starting treatment, 56.6% of patients stated that their symptoms were much less/less intense, 86% needed less symptomatic medication for control of their symptoms, and 74.4% manifested to have improved (quite/a lot) as regards their allergic disease since treatment was initiated as compared with previous grass pollen season. The patient satisfaction with GRAZAX
conclusionsIn summary, it can be concluded that improved communication leads to increased patient knowledge, greater patient compliance, and increased patient satisfaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.